Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ari B. Cuperfain, Gali Katznelson, Tianna Costa, Patrick Wong, Narges Beyraghi, Tony P. George, Michelle R. Lofwall & Nitin Chopra. (2023) Factors to guide the use of extended-release buprenorphine formulations for specific patient populations. Journal of Substance Use 0:0, pages 1-7.
Read now
Read now
Élise Lachapelle, Léonie Archambault, Camille Blouin & Michel Perreault. (2021) Perspectives of people with opioid use disorder on improving addiction treatments and services. Drugs: Education, Prevention and Policy 28:4, pages 316-327.
Read now
Read now
Graham Parsons, Cindy Ragbir, Oscar D’Agnone, Ayana Gibbs, Richard Littlewood & Bernadette Hard. (2020) Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine. Substance Abuse and Rehabilitation 11, pages 41-47.
Read now
Read now
Helen Phillips-Jackson, Clive Hallam, Niamh Cullen, Terry Pearson, Mark Gilman, Li Li & Paul Musgrave. (2020) Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements. ClinicoEconomics and Outcomes Research 12, pages 233-240.
Read now
Read now
Walter Ling, Steve Shoptaw & David Goodman-Meza. (2019) Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation. Substance Abuse and Rehabilitation 10, pages 69-78.
Read now
Read now
Articles from other publishers (18)
Simon Clay, Carla Treloar, Louisa Degenhardt, Jason Grebely, Michael Christmass, Chris Gough, Jeremy Hayllar, Mike McDonough, Charles Henderson, Sione Crawford, Michael Farrell & Alison Marshall. (2023) ‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue. International Journal of Drug Policy 115, pages 104002.
Crossref
Crossref
Joanne Neale, Stephen Parkin & John Strang. (2023) How do patients feel during the first 72 h after initiating long‐acting injectable buprenorphine? An embodied qualitative analysis. Addiction.
Crossref
Crossref
Anna Cheng, Ryan Badolato, Andrew Segoshi, Ryan McDonald, Mia Malone, Kumar Vasudevan, Beita Badiei, Allison Sugarman, Ross Macdonald, Jasdeep Mangat, Jonathan Giftos, Joshua D. Lee & Babak Tofighi. (2022) Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addiction Science & Clinical Practice 17:1.
Crossref
Crossref
Natalie Lowry, Fiona Cowden, Edward Day, Eilish Gilvarry, Stacey Johnstone, Robbie Murray, Mike Kelleher, Luke Mitcheson & John Marsden. (2022) Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation. BMJ Open 12:10, pages e067194.
Crossref
Crossref
Salomon Poliwoda, Nazir Noor, Jack S. Jenkins, Cain W. Stark, Mattie Steib, Jamal Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam M. Kaye & Alan D Kaye. (2022) Buprenorphine and its formulations: a comprehensive review. Health Psychology Research 10:3.
Crossref
Crossref
Emily Martin, Hayley Maher, Gemma McKeon, Sue Patterson, Julie Blake & Kai Yang Chen. (2022) Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health. Journal of Substance Abuse Treatment 139, pages 108776.
Crossref
Crossref
Francisco Salvador Pascual, Alvaro Muñoz, Rodrigo Oraa, Gerardo Flórez, Pilar Notario, Pedro Seijo, Begoña Gonzalvo, Carla Assaf, Manuel Gómez & Miguel Ángel Casado. (2022) Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study. European Addiction Research 28:2, pages 143-154.
Crossref
Crossref
Lorenzo Somaini, Sarah Vecchio, Camilla Corte, Carmen Coppola, Aisling Mahony, Alexandra Pitts, Manuela Cutuli, Rosetta Orso & Richard Littlewood. (2021) Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life. Cureus.
Crossref
Crossref
M. McNicholas, M. Scully & E. Keenan. (2021) An overview of recent advances in opioid agonist treatment (OAT). Irish Journal of Psychological Medicine, pages 1-3.
Crossref
Crossref
Evan S. Cole, Coleman Drake, Ellen DiDomenico, Michael Sharbaugh, Joo Yeon Kim, Dylan Nagy, Gerald Cochran, Adam J. Gordon, Walid F. Gellad, Janice Pringle, Jack Warwick, Chung-Chou H. Chang, Julie Kmiec, David Kelley & Julie M. Donohue. (2021) Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population. Drug and Alcohol Dependence 221, pages 108633.
Crossref
Crossref
Bernadette Hard. (2021) Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence. Case Reports in Psychiatry 2021, pages 1-3.
Crossref
Crossref
Michael Soyka. (2020) Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update. Pharmacopsychiatry 54:01, pages 18-22.
Crossref
Crossref
Jason Grebely, Magdalena Cerdá & Tim Rhodes. (2020) COVID-19 and the health of people who use drugs: What is and what could be?. International Journal of Drug Policy 83, pages 102958.
Crossref
Crossref
Briony Larance, Louisa Degenhardt, Jason Grebely, Suzanne Nielsen, Raimondo Bruno, Paul Dietze, Kari Lancaster, Sarah Larney, Thomas SantoJrJr, Marian Shanahan, Sonja Memedovic, Robert Ali & Michael Farrell. (2020) Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction 115:7, pages 1295-1305.
Crossref
Crossref
Elizabeth C. Saunders, Sarah K. Moore, Olivia Walsh, Stephen A. Metcalf, Alan J. Budney, Emily Scherer & Lisa A. Marsch. (2020) Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. Journal of Substance Abuse Treatment 111, pages 54-66.
Crossref
Crossref
Joanne Neale, Charlotte N. E. Tompkins & John Strang. (2019) Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduction Journal 16:1.
Crossref
Crossref
Charlotte N.E. Tompkins, Joanne Neale & John Strang. (2019) Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. Journal of Substance Abuse Treatment 104, pages 64-71.
Crossref
Crossref
Oscar D’Agnone. (2019) Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine. Case Reports in Psychiatry 2019, pages 1-4.
Crossref
Crossref